Diabetic Peripheral Neuropathy Epidemiology Insights

DelveInsight’s ‘Diabetic Peripheral Neuropathy (DPN) - Epidemiology Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology trends of Diabetic Peripheral Neuropathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan


Study Period: 2017–2030


Diabetic Peripheral Neuropathy - Disease Understanding

Diabetic peripheral neuropathy (DPN) also known distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.

The signs and symptoms of DPN include numbness, tingling, poor balance, pain: burning, electric shocks, stabbing, spontaneous pain at the affected site, hypersensitive to pain against nociceptive warmth stimulation, and others.

The clinical manifestations of DPN include painful diabetic neuropathy (pDPN) that is often accompanied by burning pain, aching, shooting, stabbing and paresthesia or allodynia often present in arms, hands, legs, and feet. DPN without painful symptoms is referred to as nonpainful diabetic neuropathy (non-pDPN). Due to the presence of pain, pDPN patients are expected to get diagnosed and expected to incur higher health care costs compared to the general population and non-pDPN.


Diabetic Peripheral Neuropathy – Epidemiology

The Diabetic Peripheral Neuropathy epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.

DelveInsight’s estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017. Among 7MM, United States has the prevalent population of Diabetic Peripheral Neuropathy with about 12,522,483 cases in 2017. Among EU-5 countries, Germany has the highest prevalent cases with 3,904,730 cases, followed by Italy with 1,636,426 cases in 2017. However, Spain has the least number of diagnosed prevalent cases.

In 2017, the prevalent population of Diabetic Peripheral Neuropathy in Japan was found to be approximately 2,332 cases.


Diabetic Peripheral Neuropathy Report Insights

• The report covers a descriptive overview of the Diabetic Peripheral Neuropathy explaining its causes, risk factors, pathophysiology and diagnosis.

• Comprehensive insight has been provided into the epidemiology Diabetic Peripheral Neuropathy in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Assesses growth opportunities in the 7MM countries with respect to the patient population.

Diabetic Peripheral Neuropathy Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Total Patient Pool with Diabetic Peripheral Neuropathy

• Gender-Specific Patient Pool of Diabetic Peripheral Neuropathy

• Painful DPN Patient Pool


Diabetic Peripheral Neuropathy Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles


Key Benefits

• Key assessments

• Patient Segmentation

• Disease Risk & Burden

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy (DPN): Patient Overview at a Glance

3.1. Total Patient Share (%) Distribution of DPN in 2017

3.2. Total Patient Share (%) Distribution of DPN in 2030

4. Epidemiology Methodology

5. Disease Background and Overview: Diabetic Peripheral Neuropathy (DPN)

5.1. Introduction

5.2. Classification of Diabetic Neuropathies

5.3. Signs and Symptoms

5.4. Risk Factors

5.5. Pathogenesis

5.6. Diagnosis

5.7. Recent developments in early diagnosis of DPN with POCDs

5.8. Differential Diagnosis

6. Epidemiology and Patient Population: Diabetic Peripheral Neuropathy (DPN)

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy (DPN) in 7MM

6.3. United States

6.3.1. Assumptions and Rationale

6.3.2. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the United States

6.3.3. Gender-Specific Cases of Diabetic Peripheral Neuropathy in the United States

6.3.4. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the United States

6.4. EU5

6.4.1. Assumptions and Rationale

6.5. Germany

6.5.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Germany

6.5.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Germany

6.5.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Germany

6.6. France

6.6.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in France

6.6.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in France

6.6.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in France

6.7. Italy

6.7.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Italy

6.7.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Italy

6.7.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Italy

6.8. Spain

6.8.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Spain

6.8.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Spain

6.8.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Spain

6.9. United Kingdom (UK)

6.9.1. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the UK

6.9.2. Gender-Specific Cases of Diabetic Peripheral Neuropathy in the UK

6.9.3. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the UK

6.10. Japan

6.10.1. Assumptions and Rationale

6.10.2. Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Japan

6.10.3. Gender-Specific Cases of Diabetic Peripheral Neuropathy in Japan

6.10.4. Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Japan

7. Treatment and Management of DPN

7.1. Guidelines for the management of DPN

8. Unmet need

9. Bibliography

10. Appendix

11. Report Methodology

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight


Table 1: Classification for diabetic neuropathies

Table 2: Symptoms and signs of DPN

Table 3: The Toronto Diabetic Neuropathy Diagnostic definition

Table 4: A summary of the common tests used to assess neuropathy

Table 5: Screening and Diagnosis Recommendations by the American Diabetes Association

Table 6: Guidelines recommend the frequency and mode of assessment

Table 7: Clinical utility of devices used for the diagnosis of diabetic peripheral neuropathy

Table 8: Differential diagnosis of diabetic neuropathies

Table 9: Total Diagnosed Prevalent cases of DPN in 7MM (2017–2030)

Table 10: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Table 11: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Table 12: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the US (2017–2030)

Table 13: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Table 14: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Table 15: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Germany (2017–2030)

Table 16: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Table 17: Gender-Specific Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Table 18: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in France (2017–2030)

Table 19: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Table 20: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Table 21: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Italy (2017–2030)

Table 22: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Table 23: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Table 24: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Spain (2017–2030)

Table 25: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Table 26: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Table 27: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the UK (2017–2030)

Table 28: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Table 29: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Table 30: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Japan 2017–2030)

Figure 1: Epidemiology Methodology

Figure 2: Classification of DPN

Figure 3: Clinical presentation of small and large fiber neuropathies

Figure 4: Signs and Symptoms of DPN

Figure 5: Risk factors of DPN

Figure 6: Risk factors of painful-DPN

Figure 7: Pathogenesis of diabetic neuropathy

Figure 8: Mechanisms of diabetic neuropathy

Figure 9: Total Diagnosed Prevalent cases of DPN in 7MM (2017–2030)

Figure 10: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Figure 11: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the US (2017–2030)

Figure 12: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the US (2017–2030)

Figure 13: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Figure 14: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Germany (2017–2030)

Figure 15: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Germany (2017–2030)

Figure 16: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Figure 17: Gender-Specific Cases of Diabetic Peripheral Neuropathy in France (2017–2030)

Figure 18: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in France (2017–2030)

Figure 19: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Figure 20: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Italy (2017–2030)

Figure 21: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Italy (2017–2030)

Figure 22: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Figure 23: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Spain (2017–2030)

Figure 24: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Spain (2017–2030)

Figure 25: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Figure 26: Gender-Specific Cases of Diabetic Peripheral Neuropathy in the UK (2017–2030)

Figure 27: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in the UK (2017–2030)

Figure 28: Total Diagnosed Prevalent Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Figure 29: Gender-Specific Cases of Diabetic Peripheral Neuropathy in Japan (2017–2030)

Figure 30: Total Prevalent Cases of Painful Diabetic Peripheral Neuropathy in Japan (2017–2030)

  • Tags:
  • Diabetic Peripheral Neuropathy Epid...
  • Diabetic Peripheral Neuropathy
  • Diabetic Peripheral Neuropathy Pi...
  • Diabetic Peripheral Neuropathy Co...
  • Diabetic Peripheral Neuropathy pr...
  • Diabetic Peripheral Neuropathy in...
  • Diabetic Peripheral Neuropathy pa...
  • Diabetic Peripheral Neuropathy tr...

Forward to Friend

Need A Quote